new results study was announced on NEJM We found that semaglutide led to significant reductions in weight loss and heart failure-related symptoms in patients with obesity-related heart failure with preserved ejection fraction and T2D compared to placebo.

In the trial, called STEP-HFpEF DM, researchers compared 616 heart failure patients with preserved ejection fraction, BMI ≥30, and T2D to those who received weekly injections of semaglutide 2.4 mg or a placebo for 1 year. Randomly assigned.

The mean change in the primary endpoint, the Kansas City Cardiomyopathy Questionnaire Clinical Summary score, was 13.7 points with semaglutide compared to 6.4 points with placebo. The second primary endpoint, mean change in body weight, was -9.8% with semaglutide compared to -3.4% with placebo.

Confirmatory secondary endpoint data (change in 6-minute walk distance, hierarchical composite endpoint win rate, and change in C-reactive protein levels) also favored semaglutide over placebo. Additionally, semaglutide was associated with fewer serious adverse events compared with placebo.